HUE025336T2 - Nem nukleozid reverz transzkriptáz inhibitorok - Google Patents

Nem nukleozid reverz transzkriptáz inhibitorok Download PDF

Info

Publication number
HUE025336T2
HUE025336T2 HUE11761856A HUE11761856A HUE025336T2 HU E025336 T2 HUE025336 T2 HU E025336T2 HU E11761856 A HUE11761856 A HU E11761856A HU E11761856 A HUE11761856 A HU E11761856A HU E025336 T2 HUE025336 T2 HU E025336T2
Authority
HU
Hungary
Prior art keywords
alkyl
hiv
compound
independently
haloalkyl
Prior art date
Application number
HUE11761856A
Other languages
English (en)
Inventor
Jason Burch
Bernard Cote
Natalie Nguyen
Chun Sing Li
Miguel St-Onge
Danny Gauvreau
Original Assignee
Merck Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44710363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE025336(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Canada Inc filed Critical Merck Canada Inc
Publication of HUE025336T2 publication Critical patent/HUE025336T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)

Claims (3)

  1. L A ká$st ï ««eristf v#3®*l«:
    vagy samk gyOgyassiOsssükg 0%&amp;dl;.a;6 g*js} ahoi: Rs Cm« silói CycA, vagy AryÂ: CföA Cm «ö&amp;l *. -o^WsMissa VW M smOyM aündegyike fsggsttekk asibgfe, Cw äft » C*&amp;* Okik Cu ^ O-Cx* MsfRÄiR âigA sáisínsiv S»»se» :t*« ^s^R«et*sW. *»*·' (?) OP s^bsstisssns î'Axskgpk t«ggs;î*siû!: CO%Ä :: (2)€HJ^feg&amp;Ä :: p) C*.ft· Äl s^skspipálíp w* 1 - j s?asbs2tipssss«l ss$A2ÿ«kss^kgy jkS iSggÄ#OA, (K-s. Ä älkll O^^opÄi, €NÄ* NC#>^ ϋ®}Β®*^Μ®β** £<»* »*. Wi;Wy tXßkWf^ NpAjÜCkRs: N{E*ppykP N{RA}$(ökK{RA}R*< C<XO)N(Rptp (OC^älkSaii ρ> Cm sÄftß sswbasÂàM vss 1x5 ^bpkm&amp;ssl asxsPs^k PPspi&amp;s OggiOwui OH, 0» ¢, ^ ¾ ORPMOôgMkMl, CM NOj, PCEpÄ C(0}'M{Ra)R8; C(0)X\ C0#\ SRa. S(0}RC $(Q>&amp;\ SiO}#iRÄ)Rf\ m-*WQ0*i mW. MpÄ?«RlR"}RS< GC(OJNiR*>&amp;*. ^RaKXô}^R*îR*, vsgy NCR·* JCCÖAm'lR·^ (6) Ox* S%í:*t> (7? CH 0mB 8&amp;ib^äsÄ?&amp; vm 1-4 ssufetiRïssssaj, 8«ϊφ*&amp; fSsgsUmuî OH : 0· C:,> OPI Ο-C,* MkpOíPksl CH. Ν% H0C}Rs, C(0)N(RA1SÇ C{0)RP COPP S&amp;\S(0)R R &amp;0)P. Í(0)sK(RpR:\ S{RK}CiQ}K\ >^%0#s5 K|R*)ifO)sR*,ÇM^SPI^<RA}R8, Ο€ΧΟ)Ν0Τ>&amp;*\ tm^ciow^'íp^ vw m O-Cs.s ztei> {p <Μρ ipiSgMsBiäl ppoi,:: :ii...P;........ (I ;} tmat-i <0)N0>, (14) H(Rp§P (ii· C;Q}M(Ra}^!: pA (m) C(Cp:\ (17) C(0>-C.« feslögéstóká, (:!$)C(DR}RÄ, (1$) ÖCtÜM^}#, (20) SR”, (21) $(00 \ (22) $(C%2:\ {23) S(0};NCRÓRs, CiOlKCROSCOljR^ ;2S}N(R')S(O),qg:0R;\ {26}H(r0CÍÖ}RX (27) MEOC(C?JN(ROKO (20) N(0a;CsO?'-C(O}O;RORs, vagy mwA)oo&amp;9>&amp; (ii) 0-2 s^bssRiSxssas Äckg# lSggstl«s02 (1} ClyjQ, (2) AayQ, (?) HstQ, (4; Hi«, (S5?--€yvQ, (0} AAayQ, (?) }·}1®0?; (0) 1-HisR, (0) Cj.s .slkil syvbsatiOálvs vsa k4v«4kas0vd: CyíQv ArgO> lAsQ, J-CysQ, .?«Ary0> A BstqvsgyMkiR. {10} cu aíks-nsl ssmhsztíMM- 9m RÔvs&amp;sKRAl: CyOy AtyO, MaA), l-ksiR OCyK}. J-AïÿQ, J-Ha‘C\. vagy AHstR, vagy (!!) 1¾ alkmO -assteOMlvs vas I0vsfe;;őys!: CyçQ, Ayyl>, HaîQ, HetR, ACycQ, AArRy A Hs-O. vsgy ,J-H*1.H,: ssksfegyl CyaQ OggOOsO C>$ üÄÄä vagy %*· dkla&amp;ttask s&amp;ö) » clRbslkO vagy OläßKkcsil ösöiösOlisas ssOastksálva vas Μ· so-Oykk xsksásgylfe f%gstOsO Rs.OgOy CRa sáli OH, O-Cy a:kO 0,« OslöglgHMk vagy OAl^ Imlög&amp;íslkíA s»q<fegy)k AsyQ OlggOSsslI (Vsat vagy sssÁ ab>) s 1001 mgy zttM öpdvsáiigs» ssséaaORHh-a vsa 1-0 ssOssAovsíVötó, ssmlyôk íOsáagylks Ogg^asäl Megé% €$> MA, €j-.á alkil, Cä. e OK. 0-C;., Okít D-C-a l^bgés&amp;lki, H(RÓRS, €(0)H(Ra}Rsx 0(0)20, CO^ó $E:\ m}&amp;\ OOjMRORŐ m* SOOICR^liORiX ísrÚKÍegyik H«tQ «p fes'.sttxsíiL stfiely öpciosáUsaa $tub»»ítutóva w* 1-4 m^isífcíéíisssőL :¾.¾¾¾¾¾ srip&amp;pE® $9fgB&amp;e$ IPbp«, 0« sCkii, €*<$ Mögéxsalkil, ÔHÿ 04¾.¾ sEál..·
    0-Ci4 "toâw&amp;>M, M(EAms, €40Wt%*· <$$*·*> Φ0* Sftflf, **8y N(R0CO51í:: C; váaás0k S# ügg^lssöf-sp? *sgv *Aste>? Ä gy&amp;bL saas-iy öKtelassz k\p?sbb sgy s^sa&amp;ftsss is î*4,h$mm$émi »»»{>· fűggsílssál :&amp;s Ät vàtemm bh Qès· S iïls *fed Op^öfss-Iisss adÄ-Sp) «sgy -és sÉôi s Issfec vagy tdfeíkn tóeKíeMíhis gjfM ppsiksÄss» :SÄs«ktii&amp;!vs «sa i-4 sgalig^ísíőMSss, séh%$S sïï«i%ÿsfe® Sggeüsaää tóígp m> €s* mà% OE, m, ß-<4« Ä tie ÂpîÂl, 04::,¾ &amp;φφ&amp;, X 0'VOK XN"VxOv rixxtKi«Myik J ISgpífeaök »O, ÜO S, :.; (1) ¾ Ei!!!! (pSpl fv)i>-<:y*ElEp4 |vj) S-Cs* sSiiE^s: (vb) S(0;-C:* ôilcS^s^ (vjit) ${0}(-€< Sikä!««,. i'sx) EíTíA), vagy 0)H{R0-C;.,siyfe; E2 is Se sxl-sks-ayxl; tp-pkuSÍ: CD H, (2) €;.$ sM, :; ()}C:.ÿ:iâ;Î5p*kk:ü. (4) 0.¾ iM ssöjfejsaálva imp 14 ^$m*mm C>-C,. , mi <κ%* m ·€φρ(κΛ:&amp;* c(Q)K\ SRj mw\ m);K\ S<ü};N(REe1 NC^jeppf, M{R1€0-r\ OQOJNiR*»0, ÇS) 04):,¾ silly SiSk^Eïôî ® ^ Mk«feó¥sí; 01,0½ ·*&amp;&amp; oCi4 H&amp;íagésEMt m ecrI#, ecomrísI c£0>&amp;\ co*ra* ss ‘s -mn** mr ('?jÍPí5ppí: (SäCN, 4.4¾¾ ir UÖ)NíR1R!\ ci í) ccoíKCE^r. :il (\2)C(Q)X\ ::: ()4} C(0}<}R'\ ()5?DC{0)Ba. a#CK:(0^pAp.8t (ms.R;\ p}IÍÖ)ÍPs (’Rí S(0)PA, pt s^sp^p*, p):NppS(D}p\ (22) NpppOlpiFpRR (23) ÎSÎCKA}C(0}Rs (»^ICÇOPCR^ (25) NiPiCiOKFOppRïR* (26} N'pA)ÇOiRs <2?>N(R;pR (28;α&amp;)Νϊ^)1* (2p CXROíNCR^R* 0iyW^m$0Mh (34) C>s cikbstkil {35}0-Cu«{Rli>sRd;.: (36) AtyX, vagy 0?}ΗΧΧ; «M AtyX'Mfc %gSi(»fiäi 8- Ä Mossak, <R Stopok fög^sfä) P g) SiMi: €R ##®f €},s i&amp;SíKíikö; Aïÿ&amp;*«# ^^0^0 Αφ<0*8δΚ; lipRi'íssk asv*a*?. s áefmiciója,· a#ï HsR%ssR; E* H'vspfC^ sMíí Äl4|)%:pi).. Isp^i {0 »$* {Ül m %' :W l{î'·^# Mentek pssosâifeksrbçÂàss s^ítesásasí; sappssH lepIRbfe «§5? §pp ssokä v&amp;gy (¾ ΐ ( - (4-s.&amp;gö tsssiKlpus, swaismk kâàw^Âfp^K55àw%'SH^I»8»fe^Îiàllb·^'^^· S«833^ î&amp;iÂg^RÎ4i?#p ^0»mi m ms- Φ&amp;* SS5ö|a M ^sfttersaîanüôti sstóy Rigggpsis Ri ym s4RsssPâ N« O 4* S K6s§k shc-i -««Kkgyp 0s 8ps»s«»ásisáa. %2 ííxsd alakkss vas askgs, vsgy (it) agy 9» vagy lO*t&amp;gv ae&amp;&amp;bbísi&amp;»isa*%. $**®k*k gyí&amp;&amp;íei*áswfc*k &amp;$*·$ SKtsIssss: M* Mí^assKik amát« ij|g«tk'sSi kïv&amp;v vsksass·* K. 0 è* S k&amp;sùl» tói &amp; gyik&amp;k egvtó ' S^j-»»jïAg^i* ísmímse. vágy ishh &amp;gÂ&amp;· agy ψ$β $*ρφ, mveé^à K ^ím?tó8» ϊνάά sisípbss vrn&amp;im* # íRsktegysk S jgy&amp;jiíöR 'VS%«83*sÿ :%Mp &amp;Ö) Y*# mk Msdsgvik $t ^jp*l«sp H. vagy C*#d% svisdagylsR8 %pfca&amp;: H v«gy C^sRvk ás MMsgyfk U &amp;sgfä: wfffUH ä ÄögsöÄ atsdyta miÄP Mg «§y MMít vagy ÂÎfcsa satu mé *®Φ rn^mm mm* ta'mœ» $smiyîi&amp; Xe és # kSiÄ aki » fevkbk fammmt® h m&amp; vàkssxva N; Ô, ás S RSMl; .4ÉÉ * cp^állssgs^ámM^ vm 1 vagy 3 s^fessiÄs&amp;M amelyek îsîs^IM C^ sllílk éi.0jR^ C(0)OR.'\ CíO)N(F.A}Rs, vagy SsO'hE*; «s «Ml m ?#m»sálís S a gyüröbeg «pfesâMas S«)s Mgy S(Oyvglfis|lbSk vsa jéte».: ,% μ i, fämypm- *spm mm ôiibgMiïSÎô φ* émi km feiigsfóls tel ^é>«jl»á''i«N^^'lvs,ve»· 1.4: ^ÉP*.4:M^lssW^ t^lfeaq#: (DC^aikig a)Çaifcsi«#ssM>: (?) 0*C}.* titë. (·*) balog·««. (S)CKí, |0S^Hsitófysgy (B OpQ, smá * ss®* mm. 4W ^ufcaátífcm· tÿ®&amp; &amp; -tói' Cyvij ^.r íSfesltó. 3, A* ïdgéwypontsaetiaSi vagyak« vagy a*sak gyógyssexávsaufeg dtbpyható sw&amp;, Mól: RÎ: (?) C;,4 Síkií. (2) C:..< bafcgésMksl (BCKbaSM. (4) O-Cja íss;{>gé«slkjí; (SJMsgsfe. (6}S~C:.4«iM.vagy C?}C^dkk*&amp;ik i R3: (DR Ik) C ;..< sl'ak· 14} g-CH sikíú ($} Ό-Cm ($) s&amp;lôgés. (?) S Cm sikil vsgy (S) C;,>:Î;îkk>slkil·; As B.4 H.
  2. 4, As 1. igssypöss gjwt«8* wSlst, **8? assssîe- gpgys^ésssCkg ^%gs4hs«4 soky apCv «gy k#ki. il ssensk 'Ag>Ckift
    shah X1 ès Xs sikckgysk fggggîisssik: (1>H> (2) Cm alklk (3) Cm ksfegâsslH!, (4) Cm sitexti, (5) CM Ami kkCsssMssM v&amp;« CN*«1» /6} ô!i (7) OC;,; «ik&amp; (g) D'Cs ..> kk#88Ítö> (9) halogén,. ÜOjCN. CCMC (0)'M(RA)ES: (î7H4ÜiC(RA;k7 (H} 0(0)R* a:cco5rt (MSK.\ (Π) $(0)C\ (1Ç $C;R\ tm SOskiRA)Ss; (2Ô) S<CN(RA}CiO)R!î. vâgv ixùssfesyxk CÿsQ C*} çiHoâ&amp;Ü, nM s OkfcORil ögeksOissss ÿsuksaiïîKàSvs va^ i.~3 S^steU$i$«ä«ek §ï?seîyôk &amp;5i&amp;<l&amp;gy(kc fö^ftóss§s issïôgè».. 0;,.< Síkú, Oit, 0'-C;...i Sïks.î, 1-::4 ftsfogè'r.sskiL vagy 0-0:,.¾ hsjfcgéssM; R,î,ës (O jr,vïKfegyik« S§**t!:«s8l: (1} H, C2)Cs.asM}s (3) €).<. feslsgteM, (4) ŒjOH, (5) CHvCKk. slRik (6· C!-k£55k |?}ai*N{RA)R5» Ck} <:Hî:CîOPCRa}Hs; (OCHooomO (H5) C%Cô;E\ (η)αι^(θ;#Λ. 02}0-C^slksit (13) ô-Cm kkhpssM!* (14) k0(ssgéi% 05} CR ...... ............................................. (!§) KOj, (Π}Ν{Κλ)0!\ (Ik) &amp;OW0^ß\ (19) €{0)Ά\ (2(5} €(0.00,¾ hO^gstmíML (2 5}C(ö}<5RA (22) Sk.\ (23) S(OhEA·
    vagy msvkgyík V 8¾.¾¾¾¾¾¾} Hs 0¾ C(0)<Mi, Ç{ô)0€M$f vagy 'S<0)iCtí^ Tis H vagy C;..i sík«; â&amp;isdsgyîk RA IÜ|g8t;«5Jüi ü vagy «isik és ««íK^yík E.i! Έ Ct„« sitó. S. Az 1:. vsgy 4, ié*ÿ$mt sgw«ti vssy&amp;iö! vsgy saMí ^%yssssÄÄg ©I fegs#®íé s4i% aSwii X1· és Xs í&amp;lsáégyslc íuggs'tisssül' {2} €:,4 %çp$djL P)Ö-C<.4 3&amp;5L (4) h&amp;lií$é&amp;<. CttCN, (δ) S-Cs,,: stkd, yä$y f?)Cy«Q; έ» feUsve, ttgy (1) síss: Aisb, ïsûm így »shmk»«*» CyçQ, As «àc4 CysQ €>.·; ttktoaskil; «s (is) X' &amp; 3CX l«gslslá> sgyj&amp;ö sxáX mini H; Itt: <ï> Ci.*-«ISciís (2) Cj,,4ÍíSÍ'ysIM, (3) í>C:,.s slttb- (4) 0-€4..yfl»ô5yJkîï} (3) ksttgssy (fi) S-Ci.4 Sild!, v&amp;gy (;) C(v? sitóosM; Itt: om (2) CV4 aiXi, (2) hsk^g&amp;íKiikii, (4> ö'Ci.4 stkik (3) 0'€í4 S«ss»%ii, (ttlsslôgàî, (7) S-'Cu »Skß, vagy (3) Cj,:? sttl«ttkii; és Es H vagi' Ä 3, A® 1„ .4. sssgy .·&amp; ig4«>F««ttk. vsgyikA %s$y ssíssk gydgysssttsasdkg ttfbp#stt ttjX shot 3 y§gyüfd. Mpkt-MI ddtttt:
  3. 7, As A 4-4, igssîypïmttkAk bmmiyè® mmű vgpaid: v&amp;gy ssstt:: gYô7ysxe?éd*j:tt« Âp4h&amp;|Èè tttt Xs CI-I> vggy CH-A'Ai,.. $f Az L 4-1. igsssjfogískiök s-sedrni vsgyükt vsgy m&amp;k gykpssÆksskkg Äsp#sat&amp; »öjäv sàof Μ, -¾ As Ï, kèmwtâ sss^ök ϊφΐ« J 444mü vsgyii^, iàol s v§g$Ä U vas vs|»tvs s si k vSispïÎfikü:
    és smsfe pé&amp;^wfessâ&amp;sf ÂgaAâ*ô kgs. s 0. Âs 1. igényi? ssssfîîîîï kkslsi $ szmâiâ vsgysisg Auky
    ! 1, AS 1. ifêïïypiîSt 8SSASÖ képis* 1 smkg vsgyûkî gyègy8*«yfe«ik% diop#s&amp; s^A meify·
    Il> iÄsssÄBi äjr«!v -sxÄaggs &amp;k nmaë vsgy^ vsgÿ snask g>4ps^sg®Äg «j&amp;gädssä!® s#s Míásos sssnyvtógév és gyögysx«4syenkg s!fogsíi»&amp;i;> feikiKÔsçfSÿs^ôi U.. ©ÿégÿssigïteM "j^asps^Ä, hhHs««®« &amp; |;ö» igés;á*M v®|ySki $φ&amp;ρχψ ÄS ^gSfKßAseÄg. dfô|p^Â.|Èfcrteàj#ÿ»gôl. >4 Μ ί-Ä JgéOppBsíök béíaíelj'íke ss&amp;dmi vsgvSk? $»$£' vaMi gy%ÿssv^fets| «ItögsOOass ^ibssssîMfefS HIV ïiübkdé ^IläklälrS vsgy festéséi« vxgy MHS ksá-é«ete ssöIisVsss« teÄs, vagf Ääte mtém «*&amp; ÄäNrwt, Lé, Λ Ιί; iféî^f«k aaadati vsgyliieí MmmMêm Hiv ssÄcM proOkxkfe vagy fcéafti&amp;éí* vag* Ä£0S kiíSséssferpmksMá'y, kaxslks&amp;v. vsgv fcssitíSíkséía sissyas®,. «kisek er;« ssékséyyí vsa. iis, ás l-IO. Igés^Ksî Misses ssÄ vegyük? vsgy aramk gyôgysssfèssMkg diegsdtvM SíJls, MsssssÄs® gvàgÿssîf «siMOiMsto» sassly HIV iskkciè sreSkxsHs vagy ksssctésére vágy äMS Wèd**k<x. poSmiâàm. tectésérc: vagy Msklkkkks ssslgstAaÿim, «haxke-xe mlksègs v;n'~
HUE11761856A 2010-03-30 2011-03-28 Nem nukleozid reverz transzkriptáz inhibitorok HUE025336T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31882410P 2010-03-30 2010-03-30
US32157310P 2010-04-07 2010-04-07

Publications (1)

Publication Number Publication Date
HUE025336T2 true HUE025336T2 (hu) 2016-03-29

Family

ID=44710363

Family Applications (4)

Application Number Title Priority Date Filing Date
HUE15157348A HUE031785T2 (hu) 2010-03-30 2011-03-28 Gyógyszerészeti kompozíció, amely tartalmaz nem nukleozid reverz transzkriptáz inhibitort
HUE11761856A HUE025336T2 (hu) 2010-03-30 2011-03-28 Nem nukleozid reverz transzkriptáz inhibitorok
HUS1900022C HUS1900022I1 (hu) 2010-03-30 2019-04-09 Gyógyszerészeti kompozíció, amely tartalmaz nem nukleozid reverz transzkriptáz inhibitort
HUS1900021C HUS1900021I1 (hu) 2010-03-30 2019-04-09 Nem nukleozid reverz transzkriptáz inhibitorok

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE15157348A HUE031785T2 (hu) 2010-03-30 2011-03-28 Gyógyszerészeti kompozíció, amely tartalmaz nem nukleozid reverz transzkriptáz inhibitort

Family Applications After (2)

Application Number Title Priority Date Filing Date
HUS1900022C HUS1900022I1 (hu) 2010-03-30 2019-04-09 Gyógyszerészeti kompozíció, amely tartalmaz nem nukleozid reverz transzkriptáz inhibitort
HUS1900021C HUS1900021I1 (hu) 2010-03-30 2019-04-09 Nem nukleozid reverz transzkriptáz inhibitorok

Country Status (44)

Country Link
US (2) US8486975B2 (hu)
EP (2) EP2924034B1 (hu)
JP (2) JP5281718B2 (hu)
KR (1) KR101421861B1 (hu)
CN (1) CN102971308B (hu)
AR (1) AR080859A1 (hu)
AU (1) AU2011235568B2 (hu)
BR (1) BR112012024691B1 (hu)
CA (1) CA2794377C (hu)
CL (1) CL2012002744A1 (hu)
CO (1) CO6630126A2 (hu)
CR (1) CR20120503A (hu)
CY (3) CY1118774T1 (hu)
DK (2) DK2924034T3 (hu)
DO (1) DOP2012000256A (hu)
EA (1) EA024804B1 (hu)
EC (1) ECSP12012201A (hu)
ES (2) ES2536295T3 (hu)
FI (1) FIC20190021I1 (hu)
GE (1) GEP20156368B (hu)
HK (2) HK1175471A1 (hu)
HN (1) HN2012002039A (hu)
HR (2) HRP20150427T1 (hu)
HU (4) HUE031785T2 (hu)
IL (2) IL222030A (hu)
LT (3) LT2924034T (hu)
LU (2) LUC00113I2 (hu)
MA (1) MA34170B1 (hu)
ME (2) ME02570B (hu)
MX (1) MX2012011379A (hu)
MY (1) MY163979A (hu)
NI (1) NI201200146A (hu)
NL (1) NL300980I2 (hu)
NO (2) NO2019019I1 (hu)
NZ (1) NZ602670A (hu)
PE (1) PE20130158A1 (hu)
PL (2) PL2552902T3 (hu)
PT (2) PT2924034T (hu)
RS (2) RS55505B1 (hu)
SG (1) SG184347A1 (hu)
SI (2) SI2924034T1 (hu)
TN (1) TN2012000455A1 (hu)
TW (1) TWI458719B (hu)
WO (1) WO2011120133A1 (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA024804B1 (ru) * 2010-03-30 2016-10-31 Мерк Кэнэда Инк. Ненуклеозидные ингибиторы обратной транскриптазы, композиции, их содержащие, и их применение
US20140031250A1 (en) 2010-10-07 2014-01-30 David Tsai Ting Biomarkers of Cancer
BR112015005997A8 (pt) * 2012-09-26 2023-04-11 Merck Sharp & Dohme Composto
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
US9663490B2 (en) * 2012-12-05 2017-05-30 Merck Sharp & Dohme Corp. Process for making reverse transcriptase inhibitors
JP6387094B2 (ja) * 2013-11-22 2018-09-05 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 非ヌクレオシド逆転写酵素阻害剤の組成物
MX367369B (es) 2013-12-04 2019-08-16 Merck Sharp & Dohme Proceso para preparar inhibidores de la transcriptasa inversa.
WO2015153304A1 (en) * 2014-04-01 2015-10-08 Merck Sharp & Dohme Corp. Prodrugs of hiv reverse transcriptase inhibitors
US10603282B2 (en) 2015-12-02 2020-03-31 Merck Sharp & Dohme Corp. Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
WO2018175271A1 (en) * 2017-03-24 2018-09-27 Merck Sharp & Dohme Corp. Formulation for parenteral administration
AU2018255954B2 (en) 2017-04-18 2024-04-04 Cipla Limited Combination therapy for use in treating retroviral infections
EP3749330A4 (en) 2018-02-06 2021-11-17 The General Hospital Corporation REPEAT RNA AS A BIOMARKER OF TUMOR IMMUNE REACTION
CN110801455B (zh) * 2019-11-12 2020-06-02 河北医科大学第二医院 用于治疗mrsa的药物组合物及其应用
CN114163309B (zh) * 2021-12-27 2023-04-25 甘肃皓天医药科技有限责任公司 一种多拉韦林中间体的制备方法
CN114349690B (zh) * 2022-02-15 2023-04-25 甘肃皓天医药科技有限责任公司 一种多拉韦林中间体合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904045D0 (sv) 1999-11-09 1999-11-09 Astra Ab Compounds
TW200423930A (en) * 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
JP4485520B2 (ja) 2003-03-24 2010-06-23 エフ．ホフマン−ラ ロシュ アーゲー 逆転写酵素阻害剤としてのベンジル−ピリダジノン類
TW200505441A (en) * 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
US7166738B2 (en) 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
WO2005102989A1 (en) 2004-04-23 2005-11-03 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
EP1831157A2 (en) 2004-12-22 2007-09-12 Pfizer Limited Nonnucleoside inhibitors of hiv-1 reverse transcriptase
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
EP1940782B1 (en) 2005-10-19 2009-03-11 F.Hoffmann-La Roche Ag N-phenyl phenylacetamide non-nucleoside reverse transcriptase inhibitors
JP2009515826A (ja) 2005-10-19 2009-04-16 エフ．ホフマン−ラ ロシュ アーゲー フェニル−アセトアミドｎｎｒｔ阻害剤
TW200831085A (en) 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
CA2705834A1 (en) * 2007-11-20 2009-05-28 Merck Sharp & Dohme Corp. Pyridinone non-nucleoside reverse transcriptase inhibitors
EA024804B1 (ru) * 2010-03-30 2016-10-31 Мерк Кэнэда Инк. Ненуклеозидные ингибиторы обратной транскриптазы, композиции, их содержащие, и их применение

Also Published As

Publication number Publication date
PT2552902E (pt) 2015-06-02
PL2924034T3 (pl) 2017-07-31
NL300980I2 (nl) 2021-06-17
SG184347A1 (en) 2012-11-29
EA024804B1 (ru) 2016-10-31
EP2552902B1 (en) 2015-03-11
EP2924034A1 (en) 2015-09-30
CA2794377A1 (en) 2011-10-06
TW201139409A (en) 2011-11-16
US20130296382A1 (en) 2013-11-07
IL233334A (en) 2015-09-24
TWI458719B (zh) 2014-11-01
MA34170B1 (fr) 2013-04-03
ES2536295T3 (es) 2015-05-22
PE20130158A1 (es) 2013-02-28
HUS1900022I1 (hu) 2019-05-28
LTPA2019507I1 (lt) 2019-04-25
HK1175471A1 (en) 2013-07-05
ES2609636T3 (es) 2017-04-21
US8486975B2 (en) 2013-07-16
DK2552902T3 (en) 2015-06-15
ME02181B (me) 2015-10-20
SI2552902T1 (sl) 2015-10-30
NL300980I1 (nl) 2019-04-24
KR101421861B1 (ko) 2014-07-22
GEP20156368B (en) 2015-09-25
NI201200146A (es) 2013-03-18
NO2019019I1 (no) 2019-04-24
CY1118774T1 (el) 2017-07-12
KR20120128703A (ko) 2012-11-27
SI2924034T1 (sl) 2017-05-31
MY163979A (en) 2017-11-15
RS55505B1 (sr) 2017-05-31
EP2552902A4 (en) 2013-09-04
HRP20161680T1 (hr) 2017-01-27
CY2019025I1 (el) 2019-11-27
JP2013510800A (ja) 2013-03-28
EP2924034B1 (en) 2016-11-02
JP2013209405A (ja) 2013-10-10
JP5886790B2 (ja) 2016-03-16
LTC2552902I2 (lt) 2019-12-10
AR080859A1 (es) 2012-05-16
HUE031785T2 (hu) 2017-08-28
IL222030A (en) 2014-07-31
EP2552902A1 (en) 2013-02-06
PT2924034T (pt) 2017-01-06
ECSP12012201A (es) 2012-10-30
FIC20190021I1 (fi) 2019-04-17
IL233334A0 (en) 2014-09-01
NO2019018I1 (no) 2019-04-24
CY2019025I2 (el) 2019-11-27
LTC2924034I2 (lt) 2020-10-12
CA2794377C (en) 2015-06-16
CN102971308A (zh) 2013-03-13
CN102971308B (zh) 2015-02-04
HN2012002039A (es) 2015-08-24
TN2012000455A1 (en) 2014-01-30
CL2012002744A1 (es) 2012-12-14
LTPA2019506I1 (lt) 2019-04-25
LT2924034T (lt) 2016-12-27
PL2552902T3 (pl) 2015-10-30
CR20120503A (es) 2013-01-09
US20110245296A1 (en) 2011-10-06
AU2011235568B2 (en) 2013-09-12
EA201290976A1 (ru) 2013-03-29
WO2011120133A1 (en) 2011-10-06
CY2019026I2 (el) 2020-05-29
HRP20150427T1 (hr) 2015-07-03
HUS1900021I1 (hu) 2019-05-28
MX2012011379A (es) 2012-11-30
ME02570B (me) 2017-06-20
AU2011235568A1 (en) 2012-11-01
BR112012024691B1 (pt) 2020-11-17
CY2019026I1 (el) 2020-05-29
CO6630126A2 (es) 2013-03-01
RS54017B1 (en) 2015-10-30
JP5281718B2 (ja) 2013-09-04
LUC00114I1 (hu) 2019-04-17
DOP2012000256A (es) 2012-12-15
LUC00113I2 (hu) 2024-05-22
NZ602670A (en) 2014-09-26
LUC00114I2 (hu) 2020-07-10
DK2924034T3 (en) 2017-02-06
BR112012024691A2 (pt) 2019-07-02
HK1209121A1 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
HUE025336T2 (hu) Nem nukleozid reverz transzkriptáz inhibitorok
JP5327652B2 (ja) 癌処理のための融合されたイミダゾール
TW201028393A (en) Kinase inhibitors and methods of their use
WO2018177403A1 (zh) 1H-咪唑[4,5-h]喹唑啉类化合物作为蛋白激酶抑制剂
CN112513020B (zh) 用于治疗疾病的kdm1a抑制剂
CN107406438A (zh) 溴结构域的抑制剂
TW200916469A (en) Multi-cyclic compounds
WO2011098035A1 (zh) 一种青藤碱衍生物、合成方法及其用途
TW201217362A (en) Heteroaryls and uses thereof
AU2012224499A1 (en) New pyridazinone and pyridone compounds
UA125644C2 (uk) ЗАМІЩЕНІ 5,6,7,8-ТЕТРАГІДРО[1,2,4]ТРИАЗОЛО[4,3-а]ПІРИДИН-3(2Н)-ОНИ ТА 2,5,6,7-ТЕТРАГІДРО-3Н-ПІРОЛО[2,1-с][1,2,4]ТРИАЗОЛ-3-ОНИ ТА ЇХ ЗАСТОСУВАННЯ
CN115160299A (zh) 一类黄嘌呤氧化酶抑制剂
JP2008546839A (ja) 非ヌクレオシド逆転写酵素阻害剤
JP2022545686A (ja) シュウ酸関連疾患を治療するための化合物及び方法
JP2009504652A (ja) 非ヌクレオシド逆転写酵素阻害剤
CN103153991A (zh) 噻唑烷二酮化合物的合成方法
CN112533924A (zh) 作为IRAK4抑制剂的吡咯并[1,2-b]哒嗪衍生物
CN115361948A (zh) 抑制二氢乳清酸脱氢酶的方法和组合物